| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology | ||
Phase 3 Readout example | Phase 3 | — | Subscribe to access the data. | Biologics | Oncology |
Recent Updates
Recently added Catalysts
Innate Pharma S.A.$1.79
+0 (+0.14%)
C 54Pipeline Score Fair Value Biotech · Clinical
Market Cap
178.64 M
EPS
-0.61
P/E Ratio
-
Value Trade
35.25 K
-15.28 %
Week
25.34 %
1 Month
7.65 %
3 Month
0 %
6 Month
-53.66 %
5 Year
-67.38 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
11.79 K
52 Week Range
1.17 - 2.63
% held by Insiders
-
% held by Institutions
0.2 %
Enterprise Value
164.86 M
Total Shares
93.90 M
Short %
-
Float Shares
-
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Innate Pharma S.A.
403Total events
5Upcoming
67Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 5
Event history 398
May 13, 2026
May 13, 2026
◆Enrollment UpdateIPH4502Trial
Approaching completion of enrollment in Phase 1 dose escalation and backfill cohorts for IPH4502
solid tumorssource ↗
Apr 23, 2026
◆Oral PresentationPresentation
Innate Pharma to participate in D. Boral Capital Global Conference
Apr 21, 2026
▲Oral PresentationIPH5201 + durvalumab + standard chemotherapyPresentation
Interim results from MATISSE Phase 2 trial of IPH5201 presented at AACR 2026
resectable non-small cell lung cancersource ↗
Apr 21, 2026
▲Interim AnalysisIPH5201 + durvalumab + standard chemotherapyTrial
Pre-planned interim analysis of MATISSE trial on 40 patients
resectable non-small cell lung cancersource ↗
Apr 20, 2026
◆Enrollment UpdateIPH5201 + durvalumab + standard chemotherapyTrial
MATISSE trial continues to recruit patients with PD-L1≥1% tumors
resectable non-small cell lung cancersource ↗
Apr 17, 2026
▲Interim AnalysisIPH5201 + durvalumab + standard chemotherapyTrial
Pre-planned interim analysis on 40 patients shows higher pCR rates
resectable non-small cell lung cancersource ↗
Apr 17, 2026
▲Enrollment UpdateIPH5201 + durvalumab + standard chemotherapyTrial
Study continues to recruit patients with PD-L1>=1% tumors
resectable non-small cell lung cancersource ↗
Apr 16, 2026
◆Oral PresentationPresentation
Innate Pharma to present at AACR 2026 Oncology Industry Partnering Event
Apr 8, 2026
Apr 3, 2026
◆Oral PresentationPresentation
Innate Pharma to participate in Kempen Life Sciences Conference
Drug Pipeline Intelligence
C54
Pipeline Score $467M
Pipeline ValueFair Value
Valuation Signal13
Drugs Scored2.6x
rNPV / MCap Top 82%
Micro Cap (rank 165 of 911)
Percentile RankInnate Pharma S.A. carries a moderate pipeline score (54/100), with $5.0B risk-adjusted pipeline value, led by MIS416 in Secondary Progressive Multiple Sclerosis (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MIS416 Monoclonal antibody | Secondary Progressive Multiple Sclerosis | Phase 2 | NCT01191996 | 26% | $1.5B | COMPLETED | 127 | - | - | Nov 1, 2012 | - | Dec 7, 2012 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IPH5201 | resectable non-small cell lung cancer (NSCLC) | Phase 2 | 2026-04-20 | p CR rate PD L1 1 percent: 35.7%; p CR rate PD L1 50 percent: 50% Read More | Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 Read More | |
IPH5201 | resectable non-small cell lung cancer (NSCLC) | Phase 2 | 2026-04-20 | p CR rate PD L1 1 percent: 35.7%; p CR rate PD L1 50 percent: 50% Read More | Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 Read More | |
IPH5201 | resectable non-small cell lung cancer (NSCLC) | Phase 2 | 2026-04-20 | p CR rate PD L1 1 percent: 35.7%; p CR rate PD L1 50 percent: 50% Read More | Innate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026 Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IPHA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IPHA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IPHA▼ -7.1%on this news
Outcome of Innate Pharma’s 2026 Annual General Meeting
Innate Pharma SA held its Annual General Meeting on May 21, 2026, in Marseille, where all shareholder resolutions were voted on. A total of 94 votes were cast, representing a quorum of 37,136%. The results and related documents will be available on the company's website. Innate Pharma continues to develop innovative immunotherapies for cancer.
Read more →IPHA▼ -9.8%on this newsshared move
Innate Pharma to participate in the Jefferies Global Healthcare Conference
Innate Pharma announced its participation in the Jefferies Global Healthcare Conference 2026, where its executive team will engage in one-on-one investor meetings. The company focuses on developing immunotherapies for cancer patients and has a portfolio of promising assets. This participation highlights Innate's commitment to advancing its innovative therapies.
Read more →IPHAInnate Pharma Reports First Quarter 2026 Business Update and Financial Results
Innate Pharma has released its business update and financial results for the first quarter of 2026. The report includes insights into the company's performance and strategic direction. However, specific details regarding financial metrics or operational highlights were not disclosed in the article.
Read more →IPHANumber of shares and voting rights of Innate Pharma as of
Innate Pharma has released information as of April 16, 2026, regarding its total number of shares outstanding and voting rights. The total number of shares outstanding is reported to be 93,934,210, including ordinary and preferred shares. The company also noted its theoretical and exercisable voting rights, which are vital for shareholder engagement. Innate Pharma continues to develop innovative therapeutics for cancer treatment and collaborates with prominent firms like Sanofi and AstraZeneca.
Read more →IPHA▲ +7.9%on this news
Innate Pharma announces conference call and webcast for Q1 2026 Business Update Marseille, France
Innate Pharma has announced that it will hold a conference call on May 13, 2026, to update stakeholders on business progress for the first quarter of the year. The call will feature several key executives, including the CEO and Chief Medical Officer, indicating a thorough approach to communication. The company is engaged in developing immunotherapies for cancer and has a portfolio that includes several promising therapeutic candidates. This update reflects Innate Pharma's ongoing commitment to transparency and innovation in the biopharma space.
Read more →IPHA▲ +7.9%on this news
Innate Pharma organise une conférence téléphonique et un webcast pour présenter ses résultats du premier trimestre 2026
Innate Pharma has announced a conference call scheduled for May 13, 2026, to present its Q1 financial results and portfolio advancements. The call will feature key executives, including the CEO and CFO, highlighting the company's commitment to investor relations. A replay of the event will be available for 90 days post-conference.
Read more →IPHAInnate Pharma to participate in the D. Boral Capital Global Conference Marseille, France
Innate Pharma SA announced its participation in the D. Boral Capital Global Conference, where its executive team will engage in one-on-one investor meetings. The company develops immunotherapies for cancer and is actively advancing several differentiated potential therapies. This participation underscores the company's commitment to connecting with investors and showcasing its innovative pipeline. Innate Pharma is known for its collaborations with leading biopharmaceutical companies.
Read more →IPHAInnate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026
Innate Pharma announced that interim results from the MATISSE Phase 2 study of IPH5201 will be presented at the AACR Annual Meeting 2026. The study evaluates IPH5201 in combination with durvalumab and chemotherapy for resectable non-small cell lung cancer (NSCLC). Results show higher pathological complete response rates, particularly in patients with PD-L1 positive tumors.
Read more →IPHAINNATE PHARMA TO PRESENT MATISSE PHASE 2 INTERIM RESULTS OF IPH5201 IN CLINICAL TRIALS PLENARY SESSION AT AACR 2026 Encouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH52
Innate Pharma announced the presentation of interim results from the MATISSE Phase 2 study of IPH5201 at the AACR Annual Meeting 2026. The study evaluates IPH5201 in combination with durvalumab and chemotherapy for patients with resectable non-small cell lung cancer (NSCLC). Results indicate that the combination led to higher pathological complete response rates compared to benchmarks. The presentation will further detail the effectiveness of dual inhibition in enhancing anti-tumor immunity.
Read more →IPHANumber of Shares and Voting Rights of Innate Pharma as of April 9, 2026
Innate Pharma has released its total number of shares and voting rights as of April 9, 2026, in compliance with French regulations. The company distinguishes between theoretical and exercisable voting rights, ensuring market transparency. Innate Pharma is focused on developing innovative cancer immunotherapies and has collaborations with major biopharmaceutical companies.
Read more →IPHAInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026
Innate Pharma will hold its Annual General Meeting (AGM) on May 21, 2026, at its headquarters in Marseille. The meeting will include a guided tour of the company's laboratories and will be broadcast live. Shareholders must register their shares by May 14, 2026, to attend. Written questions must be submitted by May 15, 2026.
Read more →IPHA▲ +7.4%on this newsshared move
Innate Pharma to Present at the AACR 2026 Oncology Industry Partnering Event
Innate Pharma will present at the AACR Oncology Industry Partnering Event on April 16, 2026. COO Yannis Morel will discuss the company's innovative oncology pipeline, including key assets like IPH4502. The event aims to connect biotech leaders with investors, enhancing opportunities for collaboration and development in cancer therapies.
Read more →IPHAInnate Pharma to Participate in the Kempen Life Sciences Conference
Innate Pharma SA announced its participation in one-on-one investor meetings at the Kempen Life Sciences Conference. The company focuses on developing immunotherapies for cancer patients, leveraging its expertise in antibody-engineering. Innate Pharma is advancing a portfolio of differentiated therapeutics aimed at high unmet medical needs, collaborating with leading biopharmaceutical companies.
Read more →IPHAINNATE PHARMA FILES ITS 2025 UNIVERSAL REGISTRATION DOCUMENT (DOCUMENT D'ENREGISTREMENT UNIVERSEL) AND 2025 FORM 20-F ANNUAL REPORT Marseille, France
Innate Pharma announced the filing of its 2025 Universal Registration Document and Form 20-F Annual Report with the French market authority and the SEC, respectively. This filing highlights the company's commitment to regulatory compliance and transparency. Additionally, Innate Pharma is actively developing innovative immunotherapies for cancer patients and has established key collaborations with notable biopharmaceutical companies. The focus on differentiated therapeutics aims to meet high unmet medical needs in oncology.
Read more →IPHAInnate Pharma Reports Full Year 2025 Financial Results and Business Update
Innate Pharma has reported its financial results for the full year 2025, along with a business update. The article provides insights into the company's performance and strategic direction. However, specific details regarding financial metrics or future plans are not disclosed in the text provided.
Read more →IPHAInnate Pharma announces conference call and webcast for full year 2025 financial results Marseille, France
Innate Pharma has announced a conference call and webcast scheduled for March 26, 2026, at 2 p.m. CET to discuss its financial results for the full year ending December 31, 2025. Key executives from the company will participate in the event, which will also be available via telephone. Innate is recognized for developing novel immunotherapies targeting various types of cancer and continues to collaborate with major biopharmaceutical companies and academic institutions to enhance its research and innovation.
Read more →IPHAInnate Pharma to Participate in the Leerink Partners Global Healthcare Conference
Innate Pharma SA announced its participation in the 2026 Leerink Partners Global Healthcare Conference. Members of the executive team will engage in a fireside chat and one-on-one meetings. The company is focused on developing innovative immunotherapies for cancer, with a portfolio of differentiated assets targeting high unmet medical needs.
Read more →IPHANUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 31, 2025 Marseille, France
Innate Pharma has released details regarding its number of shares and voting rights as of December 31, 2025. The report indicates a total of approximately 93.7 million ordinary shares and nearly 94.5 million theoretical voting rights. The company is advancing its pipeline, which includes multiple immunotherapy candidates aimed at treating various cancers. Significant forward-looking statements mention the inherent risks related to product development and dependability on third-party manufacturers.
Read more →IPHANumber of Shares and Voting Rights of Innate Pharma as of December 18, 2025
Innate Pharma SA has released its total number of shares outstanding and voting rights as of December 18, 2025, in compliance with French regulations. The company is focused on developing immunotherapies for cancer and has several promising assets in its pipeline. It collaborates with major biopharmaceutical companies and research institutions to advance its innovative therapies.
Read more →IPHAInnate Pharma Releases Its 2026 Financial Calendar
Innate Pharma has announced its financial calendar for 2026, detailing the release of financial reports before market openings. The company is focused on developing innovative immunotherapies for cancer, with a portfolio that includes several promising candidates. Collaborations with major biopharmaceutical companies support its research efforts, though it acknowledges various risks associated with its operations.
Read more →IPHANumber of Shares and Voting Rights of Innate Pharma as of November 27, 2025
Innate Pharma has released its total number of shares and voting rights as of November 27, 2025, in compliance with French regulations. The report includes details on theoretical and exercisable voting rights. The company is focused on developing innovative cancer immunotherapies and has established collaborations with major biopharmaceutical companies.
Read more →IPHAINNATE PHARMA TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE Marseille, France
Innate Pharma SA announced its participation at the Jefferies Global Healthcare Conference scheduled for November 17, 2025. During the conference, members of the executive team will engage in one-on-one meetings and provide a presentation. The company develops immunotherapies for cancer with a focus on high unmet medical needs, showcasing innovative products like IPH4502 and lacutamab. Innate Pharma collaborates with major pharmaceutical companies and has a significant presence in the global biopharma market.
Read more →IPHA▼ -5.2%on this newsshared move
INNATE PHARMA REPORTS THIRD QUARTER 2025 BUSINESS UPDATE AND FINANCIAL RESULTS Marseille, France
Innate Pharma reported a positive business update for Q3 2025, highlighting significant advancements in its clinical programs. The company received FDA clearance to initiate the confirmatory Phase 3 trial for lacutamab, with expectations for accelerated approval in S zary syndrome. The firm is also progressing with the IPH4502 Nectin-4 ADC Phase 1 trial and anticipates key data from multiple trials in 2026. However, a decline in revenue compared to 2024 and planned layoffs reflect challenges in the current operational environment.
Read more →IPHA▲ +29.6%on this newsshared move
INNATE PHARMA ANNOUNCES FDA CLEARANCE TO PROCEED WITH TELLOMAK 3, A CONFIRMATORY PHASE 3 TRIAL OF LACUTAMAB IN CTC Marseille, France
Innate Pharma announced that the FDA has cleared the company to proceed with the TELLOMAK 3 trial, a confirmatory Phase 3 study for lacutamab in patients with cutaneous T-cell lymphomas, specifically S zary syndrome and Mycosis fungoides. The trial aims to demonstrate the efficacy of lacutamab in patients who have failed prior systemic therapy, with the potential for accelerated approval in S zary syndrome. The company plans to initiate the trial in the first half of 2026, building on positive data from the Phase 2 TELLOMAK trial. This regulatory milestone reflects optimistic expectations for advancing treatment options in this area of high unmet medical need.
Read more →IPHAINNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR THIRD QUARTER 2025 RESULTS AND BUSINESS UPDATES Marseille, France
Innate Pharma has announced a conference call scheduled for November 13, 2025, to discuss the company's third quarter results and business updates. Key executives including the CEO and Chief Medical Officer will present during this call. The company, known for developing immunotherapies for cancer, is based in Marseille, France and has a significant presence on both Euronext Paris and Nasdaq. Their innovative approaches in therapeutics are supported by collaboration with major biopharmaceutical companies.
Read more →IPHAINNATE PHARMA TO HOST ANALYST AND INVESTOR EVENT ON LACUTAMAB ON OCTOBER 28, 2025 Marseille, France
Innate Pharma announced an upcoming analyst and investor event on lacutamab scheduled for October 28, 2025, aimed at discussing its market outlook and clinical perspectives. Leading expert Dr. Pierluigi Porcu will present results from the TELLOMAK Phase 2 trial, highlighting the drug's potential for accelerated approval in cutaneous T-cell lymphoma (CTCL) and Sezary syndrome (SS). Additionally, ZS Associates will detail the U.S. CTCL patient population based on real-world claims data. Innate's management will also provide updates on the Phase 3 trial plans and regulatory pathway.
Read more →IPHAInnate Pharma announces its participation in the 25th edition of the European Midcap Event Marseille, France
Innate Pharma has announced its participation in the 25th European Midcap Event taking place in Paris from September 30 to October 1, 2025. CFO Frédéric Lombard will represent the company at this significant event that connects institutional investors with listed companies. The participation underscores Innate Pharma's strategies to advance its innovative cancer therapies while strengthening its relationships within the financial community. However, the company also noted the inherent risks and uncertainties associated with its forward-looking statements and reliance on third parties.
Read more →IPHAINNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FIRST HALF 2025 FINANCIAL RESULTS AND BUSINESS UPDATE Marseille, France
Innate Pharma has scheduled a conference call for September 17, 2025, to discuss business progress and financial results for the first half of 2025. Key executives will participate in the call to provide insights into the company's operations. This announcement highlights the ongoing development of their innovative cancer therapies, while also noting potential risks associated with their forward-looking statements and reliance on third-party manufacturers.
Read more →IPHANUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF SEPTEMBER 1, 2025 Marseille, France
On September 2, 2025, Innate Pharma SA disclosed its number of outstanding shares and voting rights as of September 1, 2025. The report included 92,185,473 ordinary shares and 6,419 preferred shares from 2016, plus 7,581 from 2017. With a total of 93,962,943 theoretical voting rights, the company emphasized compliance with regulatory standards. Alongside, Innate continues to develop various cancer immunotherapy products and maintains partnerships with leading biopharmaceutical companies.
Read more →IPHANUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF AUGUST 1, 2025 Marseille, France
Innate Pharma has announced the total number of shares outstanding and voting rights as of August 1, 2025, detailing 92,184,823 ordinary shares and 93,962,943 total theoretical voting rights. The company, based in Marseille, France, is focused on developing innovative immunotherapies for cancer, utilizing a proprietary platform for multi-specific NK cell engagers. While the company shows promise through its collaborations with major biopharmaceutical firms, it faces challenges tied to research uncertainties and regulatory approvals. This announcement reflects standard compliance with French stock market regulations.
Read more →IPHAINNATE PHARMA ANNOUNCES ITS PARTICIPATION IN BTIG VIRTUAL BIOTECHNOLOGY CONFERENCE Marseille, France
Innate Pharma has announced its participation in the BTIG Virtual Biotechnology Conference, scheduled for July 29-30, 2025. The CEO and COO will engage in discussions intended to enhance the company's visibility in the biotech sector, especially following BTIG's initiation of analyst coverage. The company develops innovative immunotherapies for cancer, indicating potential growth opportunities, although forward-looking statements identify various risks including uncertainties in clinical trials and regulatory approvals.
Read more →IPHANUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF JULY 3, 2025 Marseille, France
Innate Pharma has released its total number of shares outstanding and voting rights as of July 3, 2025. The company reported a total of 92,183,523 ordinary shares and nearly 93 million voting rights. Alongside this disclosure, Innate Pharma continues to focus on developing innovative immunotherapies for cancer, backed by various partnerships with significant biopharmaceutical companies. The report also highlights inherent risks related to their clinical trials and reliance on third-party manufacturers.
Read more →IPHAINNATE PHARMA ANNOUNCES ITS PARTICIPATION IN H.C. WAINWRIGHT AND WOLFE RESEARCH HEALTHCARE CONFERENCES Marseille, France
Innate Pharma has announced its participation in upcoming investor conferences: the H.C. Wainwright 3rd Annual Immune Cell Engager Virtual Conference on June 24, 2025, and the Wolfe Research Virtual Biotech Day on June 26, 2025. The company's executive team will represent Innate at these events, showcasing its immunotherapy developments. Innate Pharma focuses on utilizing the innate immune system through various therapeutic approaches, benefitting from collaborations with notable industry partners.
Read more →IPHAINNATE PHARMA HIGHLIGHTS PRECLINICAL ANTITUMOR ACTIVITY OF IPH6501 IN DIFFUSE LARGE B-CELL LYMPHOMA AND FOLLICULAR LYMPHOMA AT THE 2025 EUROPEAN HEMATOLOGY ASSOCIATION (EHA) CONGRESS Marseille, France
Innate Pharma presented promising preclinical data for IPH6501, highlighting its potent antitumor activity against Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL) at the 2025 European Hematology Association Congress. The data demonstrated enhanced efficacy when IPH6501 was combined with standard care R-CHOP, supporting its advanced clinical development. The findings suggest that IPH6501 could become a valuable treatment option for patients with B-cell non-Hodgkin lymphoma, particularly those who are refractory or relapsing from current therapies. Further evaluation in clinical settings is warranted to explore its full potential.
Read more →IPHAINNATE PHARMA ANNOUNCES ITS PARTICIPATION IN JEFFERIES AND GOLDMAN SACHS HEALTHCARE CONFERENCES Marseille, France
Innate Pharma SA announced its participation in important healthcare investor conferences, including the Jefferies Global Healthcare Conference and the Goldman Sachs Global Healthcare Conference, scheduled for June 2025. The company's executive team will host meetings and participate in fireside chats aimed at highlighting their advancements in cancer immunotherapy. Additionally, Innate Pharma will be represented at the ASCO Annual Meeting in Chicago, where they are anticipated to discuss their innovative drug candidates and collaborations. The opportunity to engage with investors underscores the firm's commitment to advancing its clinical programs.
Read more →IPHAOutcome of Innate Pharma's 2025 Annual General Meeting Marseille, France
Innate Pharma SA conducted its 2025 Annual General Meeting on May 22, 2025, in Marseille, where shareholders voted on the company's governance structure. Following the meeting, Innate transitioned from an Executive Board and Supervisory Board model to a Board of Directors led by newly appointed Chairman Irina Staatz Granzer and CEO Jonathan Dickinson. This change is aimed at aligning governance with international standards and enhancing value for stakeholders. The voting saw a quorum participation of 47.14% with 114 votes cast.
Read more →IPHAINNATE PHARMA HIGHLIGHTS DURABLE RESPONSES TO LACUTAMAB IN SEZARY SYNDROME AND MYCOSIS FUNGOIDES Marseille, France
Innate Pharma has announced promising long-term follow-up results from the TELLOMAK Phase 2 trial evaluating lacutamab for Sézary syndrome (SS) and mycosis fungoides (MF). The data revealed a 42.9% overall response rate in heavily pretreated SS patients, with a median duration of response of 25.6 months. Additionally, lacutamab showed a global overall response rate of 19.6% for MF patients, and it has received Breakthrough Therapy Designation from the FDA, indicating its potential in addressing critical needs in advanced CTCL.
Read more →IPHAINNATE PHARMA HIGHLIGHTS ABSTRACTS SELECTED FOR ASCO 2025 ANNUAL MEETING Marseille, France
Innate Pharma announced the acceptance of four abstracts at the ASCO 2025 Annual Meeting, focusing on its clinical drug developments, including long-term results from the TELLOMAK Phase 2 trial. These abstracts will highlight its advancements in treating peripheral T cell lymphomas and non-small cell lung cancer. The company aims to share insights into its innovative therapies and collaborations at the event, scheduled for May 30-June 3, 2025, in Chicago. This participation underscores Innate's commitment to advancing cancer treatments through ongoing research and development.
Read more →IPHAINNATE PHARMA HIGHLIGHTS ANKET ABSTRACTS SELECTED FOR THE EHA 2025 CONGRESS Marseille, France
Innate Pharma has announced the selection of an abstract regarding IPH6501 for the European Hematology Association (EHA) Congress 2025. This project focuses on a novel NK cell engager targeting CD20 B cells, showing potential in the treatment of relapsed and refractory Non-Hodgkin Lymphoma. The company also noted an abstract related to SAR'514, indicating ongoing collaborative work in the field. The presentation highlights Innate's innovative approach to cancer therapies using its proprietary ANKET platform.
Read more →IPHA▼ -12.1%on this newsshared move
INNATE PHARMA REPORTS FIRST QUARTER 2025 BUSINESS UPDATE AND FINANCIAL RESULTS Marseille, France
Innate Pharma provided a comprehensive update on its business and financials for Q1 2025, highlighting key achievements including a $15 million investment from Sanofi. The company also announced the dosing of its first patient in a Phase 1 study of IPH4502 and received FDA Breakthrough Therapy Designation for lacutamab. Despite this progress, changes in collaboration agreements and adjustments to ongoing studies reflect upcoming strategic shifts. Innate's cash position is robust, giving it financial stability into mid-2026.
Read more →IPHANUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF MAY 5, 2025 Marseille, France
Innate Pharma released an update on its total shares and voting rights as of May 5, 2025. The company reported 92,176,373 ordinary shares and a total of 92,962,943 theoretical voting rights. This disclosure is mandated by French regulations and aims to ensure market transparency. Innate Pharma is focused on developing immunotherapies for cancer, with multiple candidates in their pipeline supported by collaboration with key industry partners.
Read more →IPHAINNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR Q1 2025 BUSINESS UPDATE Marseille, France
Innate Pharma S.A. announced a conference call and webcast scheduled for May 13, 2025, to discuss its business progress for the first quarter of 2025. The executive management team will also meet with investors in New York and Boston from May 13 to 14, 2025. Innate Pharma focuses on developing immunotherapies for cancer patients and has partnered with prominent biopharmaceutical companies like Sanofi and AstraZeneca. The event will be accessible via a live webcast, and following the call, a replay will be available on their website.
Read more →IPHAINNATE PHARMA FILES ITS 2024 UNIVERSAL REGISTRATION DOCUMENT (DOCUMENT D'ENREGISTREMENT UNIVERSEL) AND 2024 ANNUAL REPORT ON FORM 20-F Marseille, France
Innate Pharma has submitted its 2024 Universal Registration Document and Annual Report on Form 20-F. This filing reinforces the company's commitment to transparency with regulatory authorities in both France and the United States. Innate Pharma, known for its innovative immunotherapies, is advancing its drug candidates, including unique NK Cell Engagers and Antibody Drug Conjugates. The company has established strong partnerships to enhance research and development, although it acknowledges associated risks in their forward-looking statements.
Read more →IPHA▲ +5.3%on this newsshared move
Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data Of Its Antibody Drug Conjugate IPH4502 At The AACR 2025 Annual Meeting Marseille, France
Innate Pharma presented preclinical efficacy data on its antibody drug conjugate IPH4502 at the AACR 2025 Annual Meeting in Marseille. The data indicated that IPH4502 exhibits superior anti-tumor activity against several cancer models, including those resistant to existing therapies. The findings support its potential development in a Phase 1 trial aimed at advanced solid tumors known to express the Nectin-4 target. The company is optimistic about the implications of these results for clinical benefit in cancer patients.
Read more →IPHAInnate Pharma Announces 15m Investment By Sanofi Marseille, France
Innate Pharma has announced a capital increase of €14.99 million, funded by an investment from Sanofi, which will contribute to the ongoing partnership between the companies. This investment will support the development of Innate's BCMA targeting ANKET program and other corporate purposes. The new shares resulting from this capital increase are expected to be listed on Euronext Paris on April 25, 2025. This move is a part of Innate's strategy to enhance its pipeline and long-term value creation.
Read more →IPHAInnate Pharma Regains Its Rights On CD123 Targeting ANKET And Announces Sanofi's Intention To Make A Strategic Investment In The Company Marseille, France
Innate Pharma has regained its rights to CD123 targeting ANKET SAR'579 while Sanofi plans a strategic investment of up to 15 million euros. This follows a review of the 2016 License Agreement, leading to Sanofi refocusing its efforts on developing SAR'514 IPH6401 for autoimmune conditions. Innate remains eligible for substantial R&D milestone payments and reports positive clinical benefits for SAR'579 in treating acute myeloid leukemia. The companies are collaborating on a transition plan for ongoing studies.
Read more →IPHAINNATE PHARMA TO HOLD ITS ANNUAL GENERAL MEETING OF SHAREHOLDERS ON MAY 22, 2025 Marseille, France
Innate Pharma SA plans to hold its annual general meeting of shareholders on May 22, 2025, at its headquarters in Marseille, France. The Notice of Meeting has been published and includes the agenda, proposed resolutions, and instructions for participation. Shareholders can also register for a tour of the company’s laboratories scheduled on the same day. The meeting will be broadcast live to ensure wider accessibility for shareholders.
Read more →IPHAINNATE PHARMA PROPOSES TO ITS SHAREHOLDERS TO TRANSFORM ITS CORPORATE GOVERNANCE STRUCTURE INTO A BOARD OF DIRECTORS AND TO CHANGE ITS COMPOSITION Marseille, France
Innate Pharma is proposing a transition from an executive board supervisory governance structure to a board of directors, aimed at simplifying management and aligning with global standards. This change will be presented to shareholders at the Annual General Meeting on May 22, 2025. Proposed changes include the appointment of new board members, including Irina Staatz-Granzer as Chairwoman and Jonathan Dickinson as CEO. The move is aimed at improving corporate governance and incorporating feedback from investors to foster continued growth.
Read more →IPHA▲ +7.3%on this news
INNATE PHARMA TO PARTICIPATE IN THE 2025 STIFEL VIRTUAL TARGETED ONCOLOGY FORUM Marseille, France
Innate Pharma has announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum scheduled for April 8-9, 2025. The event will feature a fireside chat with the company's executive team, aimed at enhancing investor relations and sharing insights into its immunotherapy pipeline. Innate Pharma develops innovative cancer treatments through its proprietary platforms, focusing on addressing various tumor types. The company's proactive approach underscores its commitment to advancing cancer immunotherapy, despite the inherent uncertainties in clinical development.
Read more →IPHA▲ +8.8%on this news
Innate Pharma Reports Full Year 2024 Financial Results And Business Update Marseille, France
Innate Pharma has announced its financial results for the year ended December 31, 2024, along with a business update highlighting key developments. The company received FDA Breakthrough Therapy Designation for lacutamab, aimed at treating relapsed or refractory Sézary syndrome, while progress was reported in clinical trials for other drug candidates like IPH6501 and IPH4502. Additionally, a strategic investment from the Institute for Follicular Lymphoma Innovation will support the development of IPH6501. Overall, Innate's financial position remains robust, with cash reserves expected to last until mid-2026.
Read more →IPHA▼ -8.1%on this newsshared move
Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected For The AACR 2025 Annual Meeting Marseille, France
Innate Pharma has announced that an abstract on its novel antibody drug conjugate, IPH4502, has been selected for presentation at the AACR 2025 Annual Meeting in Chicago. IPH4502, which targets Nectin-4, is currently undergoing a Phase 1 trial for advanced solid tumors. The drug has shown promising preclinical efficacy in various cancer models, suggesting potential beyond urothelial carcinoma. CEO Jonathan Dickinson will provide updates on the company’s pipeline during the event, reflecting Innate Pharma's commitment to advancing cancer therapeutics.
Read more →IPHAInnate Pharma Announces Its Participation In The Life Sciences Van Lanschot Kempen Conference Marseille, France
Innate Pharma S.A. has announced its participation in the Life Sciences Van Lanschot Kempen Conference scheduled for April 1-3, 2025, in Amsterdam, Netherlands. Members of its executive team will present at this investor conference, highlighting the company's developments in immunotherapies for cancer patients. Innate Pharma is known for its innovative ANKET platform and collaborations with major biopharmaceutical companies like AstraZeneca and Sanofi, focusing on cancer treatments and clinical research.
Read more →IPHAInnate Pharma announces conference call and webcast for full year 2024 financial results Marseille, France
Innate Pharma has scheduled a conference call for March 27, 2025, to discuss its financial results for the full year ending December 31, 2024. The call will feature key executives including the CEO and CFO. The company continues to develop innovative immunotherapies for cancer, highlighting its collaborations with prominent biopharmaceutical companies and research institutions. A replay of the webcast will be available for 90 days post-event on their website.
Read more →IPHAINNATE PHARMA TO PARTICIPATE IN THE 2025 LEERINK PARTNERS GLOBAL HEALTHCARE CONFERENCE Marseille, France
Innate Pharma has announced its participation in the upcoming 2025 Leerink Partners Global Healthcare Conference scheduled for March 10-12, 2025, in Miami, Florida. Members of the executive team will present and participate in one-on-one meetings, including a fireside chat on March 11. The company, focused on developing immunotherapies for cancer, will highlight its efforts and innovative portfolio to investors during the event.
Read more →IPHA▲ +20.6%on this news
Innate Pharma announces U.S. FDA granted Breakthrough Therapy Designation to lacutamab for relapsed or refractory S zary Syndrome Designation is based on TELLOMAK Phase 2 results demonstrating efficacy and a favorable sa
Innate Pharma has announced that the U.S. FDA has granted Breakthrough Therapy Designation to lacutamab for the treatment of relapsed or refractory S zary syndrome. This designation is based on efficacy and safety results from the TELLOMAK Phase 2 study, which demonstrated positive outcomes for heavily pretreated patients. The company also has an ongoing strategy to align with regulatory agencies for further clinical trials and seeks a partnership. Lacutamab is designed to provide new treatment options for patients suffering from this aggressive form of cutaneous T-cell lymphoma.
Read more →IPHAInnate Pharma Announces First Patient Dosed In Phase 1 Study Of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 In Selected Advanced Solid Tumors Marseille, France
Innate Pharma announced the first patient has been dosed in a Phase 1 study of IPH4502, an antibody-drug conjugate targeting Nectin-4 in advanced solid tumors. This innovative therapy aims to offer treatment options for cancers like breast and non-small cell lung cancer, noted for their limited treatment avenues. The trial will enroll approximately 105 patients and assess both safety and preliminary efficacy. Innate's executives highlighted the drug's unique targeting ability that could improve outcomes for patients facing treatment-resistant tumors.
Read more →IPHAINNATE PHARMA ANNOUNCES NECTIN-4 ANTIBODY DRUG CONJUGATE INVESTOR AND ANALYST EVENT IN NEW YORK Innate Pharma to highlight IPH4502, its lead Nectin-4 Antibody Drug Conjugate (ADC) program at clinical stage Marseille, Fra
Innate Pharma has announced an upcoming investor and analyst event in New York to detail its Nectin-4 antibody-drug conjugate, IPH4502. Scheduled for February 5, 2025, the event will discuss the latest developments and results pertinent to their ADC strategy. IPH4502, which targets Nectin-4 overexpressed in various solid tumors, has recently gained FDA approval to enter Phase 1 clinical trials, marking a significant advancement for the company's portfolio. The live webcast of the event will also be available for those unable to attend in person.
Read more →IPHANUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 31, 2024 Marseille, France
Innate Pharma SA has announced its total number of shares outstanding and voting rights as of December 31, 2024. The company has 83,830,336 ordinary shares and a total of 84,585,576 theoretical voting rights. Innate Pharma, a biotechnology firm based in Marseille, France, focuses on developing immunotherapies for cancer patients. However, it faces various risks related to research, clinical trials, and regulatory approvals as they progress with their product development.
Read more →IPHAInnate Pharma Announces Transformative Strategy to Accelerate Growth Marseille, France
Innate Pharma has announced a transformative strategy aimed at accelerating growth through innovative therapies and strategic partnerships. The plan focuses on the development of its proprietary ANKET NK-cell engager platform and various differentiated Antibody-Drug Conjugates (ADCs) targeting cancer and autoimmune diseases. The company's approach includes advancing late-stage assets through collaborations with established partners. CEO Jonathan Dickinson highlighted this strategy as a pathway to redefine immunotherapy and fulfill unmet patient needs while ensuring value for stakeholders.
Read more →IPHA▼ -5.1%on this news
Innate Pharma to participate in the 43 rd Annual J.P. Morgan Healthcare Conference Marseille, France
Innate Pharma has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. CEO Jonathan Dickinson and other executive board members will lead presentations and one-on-one meetings. The event will feature a live webcast of their session and highlights Innate Pharma's innovative cancer immunotherapy approaches, including monoclonal antibodies and ADCs. This participation marks an important opportunity for the company to engage with investors and industry stakeholders.
Read more →IPHA▲ +29.3%on this news
Innate Pharma Presents Lacutamab Improved Health-Related Quality Of Life Data At Ash 2024 From TELLOMAK Phase 2 Study In Patients With Cutaneous T Cell Lymphoma Marseille, France
Innate Pharma has presented new findings from the TELLOMAK Phase 2 study at the ASH 2024 Annual Meeting, indicating that lacutamab may improve health-related quality of life for patients with advanced cutaneous T cell lymphoma (CTCL). The study enrolled 163 patients and demonstrated promising reductions in itch intensity and skin-related symptoms. With improvements observed as early as Week 5, these results suggest lacutamab could offer significant relief to patients facing severe symptoms. The data highlight lacutamab's potential as a treatment option for patients with limited existing therapies.
Read more →IPHAInnate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announce up to $7.9m investment from IFLI to support IPH6501 development in Follicular Lymphoma Marseille, France
Innate Pharma has announced a significant investment from the Institute for Follicular Lymphoma Innovation (IFLI) totaling up to $7.9 million to support the development of IPH6501. This funding includes an initial $3 million upfront payment, as well as potential additional funding based on milestone achievements. The ongoing Phase 1/2 trial will now include patients with relapsed refractory follicular lymphoma, aiming to investigate the safety and efficacy of this therapeutics approach. Both organizations have expressed commitment to improving patient outcomes in non-Hodgkin lymphoma through innovative research and collaboration.
Read more →IPHAInnate Pharma highlights abstracts selected for the ASH annual meeting 2024 Marseille, France
Innate Pharma has announced that abstracts related to their lead drug lacutamab and a partnered asset SAR443579 will be presented at the ASH annual meeting 2024 in Marseille, France. The presentations will include crucial translational data and patient-reported outcomes from clinical trials. Dr. Sonia Quaratino, the Chief Medical Officer, highlighted the company's commitment to advancing treatment options for patients with relapsed or refractory conditions. Innate Pharma's research focuses on innovative immunotherapies aimed at cancer patients.
Read more →IPHA▲ +13.1%on this news
Innate Pharma Releases Its 2025 Financial Calendar Marseille, France
Innate Pharma has announced its financial calendar for 2025, detailing the publication dates for its financial statements and revenue positions. Significant dates include the release of the 2024 financial statements on March 27, 2025, and an Annual General Shareholders Meeting on May 22, 2025. The company continues to develop advanced immunotherapies for cancer, including partnerships with major companies. However, it cautions about the inherent uncertainties and risks associated with its forward-looking statements and clinical developments.
Read more →IPHAInnate Pharma Announces Publication In Science Immunology Highlighting Innovative Next-Generation ANKET IPH6501 Marseille, France
Innate Pharma announced a significant publication in Science Immunology highlighting IPH6501, a novel tetra-specific NK cell engager designed to target CD20 for treating Relapsed Refractory B-cell Non-Hodgkin Lymphoma (B-NHL). The data demonstrated substantial improvements in NK cell proliferation, cytotoxicity, and the ability of these cells to migrate to tumors. These promising results support further clinical trials and indicate IPH6501's potential as a transformative treatment in immuno-oncology.
Read more →IPHA▼ -11.8%on this news
Innate Pharma Reports Third Quarter 2024 Business Update And Financial Results Marseille, France
Innate Pharma released its third quarter 2024 business update highlighting significant regulatory advancements, including favorable FDA feedback for lacutamab and the IND clearance for IPH4502 aimed at solid tumors. The company also presented preclinical data for key products at recent oncology meetings and reported a solid cash position expected to sustain operations through the end of 2025. Jonathan Dickinson, the newly appointed CEO, expressed optimism about the company's trajectory and strategic goals while navigating some collaboration changes with Sanofi.
Read more →IPHAInnate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected For The SITC Annual Meeting 2024 Marseille, France
Innate Pharma has announced the presentation of new preclinical data at the SITC Annual Meeting 2024 regarding its proprietary cancer therapies, IPH6501 and IPH4502. The findings suggest significant advancements in their innovative antibody-drug conjugate and tetra-specific NK cell engager technologies. The data showcase promising anti-tumor efficacy and highlight the company’s commitment to developing next-generation immunotherapies. Furthermore, the FDA has cleared Innate's investigational new drug application for IPH4502, paving the way for a Phase 1 clinical study in solid tumors expressing Nectin-4.
Read more →IPHA▼ -10.5%on this newsshared move
INNATE PHARMA ANNOUNCES CONFERENCE CALL AND WEBCAST FOR THIRD QUARTER 2024 RESULTS AND BUSINESS UPDATES Marseille, France
Innate Pharma has announced a conference call scheduled for November 13, 2024, to discuss its third quarter results and business updates. Key executives, including CEO Jonathan Dickinson, will present the company's progress and developments. The firm's focus is on developing immunotherapies for cancer, utilizing various innovative platforms and programs. It also highlights its collaborations with major biopharmaceutical companies to enhance research and development efforts.
Read more →IPHA▲ +8.2%on this news
INNATE PHARMA ANNOUNCES ITS PARTICIPATION TO UPCOMING INVESTOR CONFERENCES Marseille, France
Innate Pharma SA announced its participation in several upcoming investor conferences, including events in New York, London, and Miami, scheduled between November and December 2024. The company aims to highlight its advancements in developing immunotherapies for cancer, utilizing unique therapeutic approaches such as monoclonal antibodies and Antibody Drug Conjugates. This active engagement with investors reflects Innate's growth trajectory and collaboration with reputable partners in the biopharmaceutical industry.
Read more →IPHAInnate Pharma Appoints Jonathan Dickinson As New Chief Executive Officer And Chairman Of The Executive Board Marseille, France
Innate Pharma has appointed Jonathan Dickinson as its new Chief Executive Officer and Chairman of the Executive Board, effective November 1, 2024. He succeeds interim CEO and co-founder Herv Brailly, who will support the transition in an advisory role. Dickinson has a strong background in biotech and big pharma, with significant leadership roles at Incyte, ARIAD Pharmaceuticals, and Bristol-Myers Squibb. His experience is expected to enhance the development of Innate Pharma's innovative cancer therapies and strengthen its market position.
Read more →IPHAInnate Pharma to host KOL scientific symposium on immunotherapy in New York on
Innate Pharma is set to co-host a scientific symposium on immunotherapy titled 'Next Generation Immunotherapy Discoveries' in New York on October 3, 2024. The event, organized in celebration of the company's 25th anniversary, will bring together key opinion leaders to discuss advancements in immunotherapy. Attendees will have the opportunity to engage with expert speakers during Q&A sessions. The symposium reflects Innate's commitment to advancing cancer care through innovative therapies.
Read more →IPHAInnate Pharma Announces FDA Clearance Of The IND For IPH4502, A Nectin-4 ADC To Be Developed In Solid Tumors Marseille, France
Innate Pharma has received FDA clearance for its investigational new drug application to commence a Phase 1 clinical study of IPH4502, an antibody drug conjugate targeting Nectin-4 in solid tumors. The study aims to evaluate the safety, tolerability, and preliminary efficacy of IPH4502 across various cancers, including urothelial and non-small cell lung cancer. This represents a critical step for Innate, marking the entry of its first ADC program into clinical trials. The company expects to initiate the study in the coming months.
Read more →IPHAInnate Pharma Reports First Half 2024 Business Update And Financial Results Marseille, France
Innate Pharma released its business update and financial results for the first half of 2024, reporting positive developments in its pipeline. The company highlighted successful results from the TELLOMAK Phase 2 study of lacutamab and advancement of SAR443579 to Phase 2. Innate also revealed data supporting ongoing trials and anticipates a robust cash position through 2025. The firm is focused on progressing its proprietary anti-Nectin-4 ADC, IPH45, toward Phase 1 in the second half of 2024.
Read more →IPHAMonalizumab data from NeoCOAST-2 Phase 2 study in early-stage NSCLC presented at the WCLC 2024 Marseille, France
Innate Pharma announced the presentation of interim results from the NeoCOAST-2 Phase 2 study of monalizumab at the WCLC 2024. The study aimed at evaluating the treatment's efficacy and safety in early-stage non-small cell lung cancer (NSCLC). Notably, monalizumab, when combined with durvalumab and chemotherapy, led to a 26.7% pathological complete response rate among participants. The preliminary findings highlight a manageable safety profile and the potential to enhance the effectiveness of existing treatments in this patient population.
Read more →IPHAInnate Pharma announces conference call and webcast for first half 2024 financial results and business update Marseille, France
Innate Pharma has scheduled a conference call for September 12, 2024, to discuss its financial results and business updates for the first half of 2024. Senior executives, including the CEO and Chief Medical Officer, will provide insights during the call. The event will be available via live webcast and telephone, with a replay accessible afterward. Innate Pharma is known for its innovative immunotherapies aimed at cancer treatment, with several key projects currently under development.
Read more →IPHAInnate Pharma announces its participation in the H.C. Wainwright 26th annual global investment conference Marseille, France
Innate Pharma announced its participation in the upcoming H.C. Wainwright 26th Annual Global Investment Conference, set to take place on September 10, 2024, in New York. Arvind Sood, the EVP and President of US Operations, will represent the company. Innate Pharma is recognized for its innovative cancer immunotherapies and has key partnerships with biopharmaceutical firms. The company operates globally with its headquarters in Marseille, France, and a US office in Rockville, MD.
Read more →IPHA▼ -10.6%on this news
Innate Pharma Shares Updated Results From The Sanofi Developed Blood Cancer Phase 1 2 SAR443579 IPH6101 Trial Marseille, France
Innate Pharma has shared updated results from the Phase 1/2 trial of SAR443579 IPH6101, developed in collaboration with Sanofi. The data presented at the European Hematology Association Congress highlights complete remissions in patients with relapsed or refractory acute myeloid leukemia and a favorable safety profile. The study has now progressed to the Phase 2 stage, indicating a promising future for the therapy targeting blood cancers with significant unmet needs. The ongoing research aims to further demonstrate the efficacy of this innovative NK cell engager treatment.
Read more →IPHA▲ +5.3%on this news
Innate Pharma presents positive results from TELLOMAK Phase 2 study with lacutamab in mycosis fungoides Marseille, France
Innate Pharma announced positive results from its TELLOMAK Phase 2 study of lacutamab in patients with mycosis fungoides, showing meaningful anti-tumor activity. The treatment was well-tolerated, with a favorable safety profile, and achieved an overall objective response rate of 22.4% in certain patient groups. These findings suggest lacutamab may provide an effective therapeutic option for heavily pretreated patients with advanced cutaneous T cell lymphomas. The results were presented at the ASCO 2024 Annual Meeting and support further development of the drug.
Read more →IPHAInnate Pharma announces its participation in upcoming investor conferences Marseille, France
Innate Pharma announced the participation of its executive team in several upcoming investor conferences, showcasing its commitment to engaging with the investment community. Key figures, including CEO Herv Brailly and Chief Medical Officer Sonia Quaratino, will represent the company at events in New York, Miami, and Lyon, as well as a virtual conference. The participation aims to highlight Innate Pharma's innovative immunotherapy approaches, particularly its lead programs targeting various types of lymphomas and lung cancers. The company is a clinical-stage biotech known for its proprietary ANKET platform, emphasizing its potential to advance cancer treatment.
Read more →IPHAInnate Pharma Highlights Abstracts Selected For ASCO 2024 Annual Meeting Marseille, France
Innate Pharma has announced that five of its drug candidates' abstracts have been selected for presentation at the ASCO 2024 Annual Meeting. The highlights include promising results from the TELLOMAK Phase 2 trial of lacutamab for mycosis fungoides and multiple presentations on the second-generation ANKET product, IPH6501. Additionally, AstraZeneca will present updated data on monalizumab in non-small cell lung cancer. These presentations reflect Innate Pharma's innovative approach to immunotherapy and partnerships for advancing cancer treatment.
Read more →IPHAOutcome of Innate Pharma's 2024 Annual General Meeting Marseille, France
Innate Pharma announced the results of its Annual General Meeting held on May 23, 2024, in Marseille. At the meeting, a total of 84 votes were cast, representing a quorum of 44.92%, with two Supervisory Board members being re-elected. The results and related documents will be made available on the company's website. Innate Pharma is actively working on immunotherapies for cancer, showcasing their ongoing development efforts in partnership with significant biopharmaceutical companies.
Read more →IPHA▼ -5.1%on this news
Innate Pharma Highlights Abstracts Selected For EHA 2024 Congress Marseille, France
Innate Pharma announced that four abstracts related to its drug candidates have been accepted for presentation at the EHA 2024 Congress in Madrid. Among the abstracts are two concerning SAR443579, an investigational NK cell engager under development with Sanofi, and two on IPH6501, a next-generation NK cell engager for treating specific B-cell lymphomas. The company expresses optimism about the potential of its ANKET platform to address high unmet needs in blood cancers. The congress will occur from June 13-16, 2024.
Read more →IPHAInnate Pharma Reports First Quarter 2024 Business Update And Financial Results Marseille, France
Innate Pharma has announced its first quarter 2024 business update and financial results, highlighting key developments in its pipeline. The company presented preclinical data for its anti-Nectin-4 antibody drug conjugate, IPH45, during the AACR 2024 meeting, and noted the advancement of the NK Cell Engager, SAR443579, to Phase 2 trials for blood cancers. Additionally, the firm reported a strong cash position of 113.9 million as of March 31, 2024, supporting its ongoing research and development efforts. Data from several upcoming ASCO presentations are also anticipated.
Read more →IPHAInnate Pharma announces conference call and webcast for Q1 2024 business update Marseille, France
Innate Pharma has announced a conference call scheduled for May 14, 2024, to discuss its business progress in Q1 2024. The call will feature key executives, including the CEO and Chief Medical Officer. Alongside the meeting details, the company emphasizes its innovative immunotherapy development for cancer, including collaborations with major biopharmaceutical companies. A replay of the event will be available on Innate Pharma's website after its conclusion.
Read more →IPHAInnate Pharma to hold its Annual General Meeting of shareholders on
Innate Pharma will hold its Annual General Meeting of Shareholders on May 23, 2024, at its headquarters in Marseille, France. The event is designed to facilitate shareholder participation, featuring a guided laboratory tour and live broadcast. Shareholders must register their shares in advance, and those holding bearer shares require a certificate to participate. The company's ongoing initiatives and clinical research development will be discussed during the meeting.
Read more →IPHAInnate Pharma Announces Advancement Of Sanofi-Developed Nk Cell Engager Sar443579 Iph6101 Progressing To Phase 2 For Blood Cancer Patients Marseille, France
Innate Pharma has announced that SAR443579 IPH6101, a NK cell engager developed in collaboration with Sanofi, has advanced to Phase 2 of clinical trials for blood cancers. This includes dosing of the first patient, triggering a $4 million milestone payment to Innate Pharma. The investigational therapy has received FDA Fast Track Designation and has shown promising clinical efficacy in earlier trials for patients with relapsed or refractory acute myeloid leukemia. The continued development of SAR443579 reflects Innate's commitment to tackling high unmet medical needs in oncology.
Read more →IPHAInnate Pharma Presents at AACR 2024 Preclinical Efficacy of its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate Marseille, France
Innate Pharma announced the presentation of preclinical data for its drug candidate IPH45 at the AACR Annual Meeting 2024. IPH45, a novel exatecan-Antibody Drug Conjugate targeting Nectin-4, demonstrated stronger anti-tumor efficacy than the approved drug Enfortumab Vedotin in preclinical studies. The findings support further development and indicate that IPH45 can address various solid tumors, including those that are typically refractory to EV. The company plans to progress toward a First in Human study with an IND application anticipated within the year.
Read more →IPHASummary of Consolidated Financial Statements and Notes as of
Innate Pharma reported its financial results for the year ending December 31, 2023, revealing a net loss of €7,570, an improvement from a loss of €58,103 the previous year. Although the company experienced increased revenue from collaboration and licensing agreements, its overall financial position remains precarious as total assets decreased significantly. Specifically, revenue from monalizumab has dropped markedly, raising concerns about the future performance of this asset. Other potential liabilities have also risen, adding to the financial challenges faced by the company.
Read more →IPHAInnate Pharma reports Full Year 2023 Financial Results and Business Update Positive final results of lacutamab TELLOMAK Phase 2 trial in S zary syndrome presented at ASH Annual Meeting 2023 final data in mycosis fungoide
Innate Pharma has reported positive outcomes from the TELLOMAK Phase 2 trial utilizing lacutamab for S zary syndrome. The company's financial results indicate a strong cash position, allowing operations to continue until late 2025. Innate has initiated a clinical trial for IPH6501 in B-cell Non-Hodgkin's Lymphoma and received validation through Sanofi's licensing of multiple NK cell engagers. However, the Phase 1b trial for lacutamab in PTCL won't reopen due to insufficient clinical activity, and previous concerns over patient safety have been addressed with the FDA lifting a clinical hold on the investigation.
Read more →IPHAInnate Pharma Announces Its Participation To Upcoming Investor Conference Marseille, France
Innate Pharma announced its participation in the 2nd Annual H.C. Wainwright Cell Therapy Virtual Conference scheduled for March 26, 2024. Members of the executive team, including the Chief Medical Officer and Chief Operating Officer, will represent the company. Innate Pharma focuses on developing immunotherapies for cancer patients, utilizing their proprietary platform, ANKET, for innovative treatments. The company maintains strong partnerships with leading biopharmaceutical firms to enhance research and development efforts.
Read more →IPHAInnate Pharma Announces Conference Call And Webcast For Full Year 2023 Financial Results Marseille, France
Innate Pharma has announced a conference call scheduled for March 21, 2024, to discuss its financial results for the full year ending December 31, 2023. Key executives will participate, highlighting the company's commitment to transparency with stakeholders. As a clinical-stage biotechnology company, Innate Pharma focuses on developing immunotherapies for cancer patients, utilizing its proprietary ANKET platform. The results of the upcoming call may provide insights into the company's financial health and future directions.
Read more →IPHAFirst Patient Dosed In Phase 1 2 Study Of Iph6501 In Relapsed Refractory B-Cell Non-Hodgkin's Lymphoma Phase 1 2 study is evaluating IPH6501, a first-in-class CD20-targeting tetraspecific natural killer cell engager, fro
Innate Pharma announced the dosing of the first patient in a Phase 1/2 multicenter trial analyzing the safety and tolerability of IPH6501 for patients with relapsed and/or refractory CD20-expressing B-cell non-Hodgkin's lymphoma. This innovative treatment aims to enhance the immune response by utilizing a tetraspecific natural killer cell engager, potentially offering an alternative strategy beyond traditional therapies. The study aims to enroll up to 184 patients to assess the efficacy and safety of this new therapeutic approach.
Read more →IPHAInnate Pharma To Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data At Aacr 2024 IPH45 abstract selected for oral presentation at AACR Annual Meeting 2024 Preclinical data support further development of IPH4
Innate Pharma has announced the selection of its abstract on the preclinical asset IPH45 for oral presentation at the AACR Annual Meeting 2024. IPH45 is a novel antibody drug conjugate targeting Nectin-4, which has shown effective inhibition of tumor growth in preclinical models. The findings indicate a favorable safety profile and support further clinical development. Innate is positioned to advance IPH45 towards human studies amid a growing interest in innovative cancer therapies.
Read more →IPHAInnate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program FDA lifts partial clinical hold on lacutamab clinical program Fatal case related to disease progression and unrelated to the trea
Innate Pharma has announced that the U.S. FDA has lifted the partial clinical hold on its lacutamab IND. This decision followed an in-depth review of a fatal case in the TELLOMAK study, which the FDA and Innate determined was related to disease progression and not the treatment itself. The lacutamab program will continue following positive results released at the ASH Annual Meeting 2023, with final data expected soon for Mycosis Fungoides. Lacutamab is currently being investigated for advanced stages of cutaneous T-cell lymphoma and peripheral T-cell lymphoma.
Read more →IPHAInnate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board Two new Executive Board members appointed under recently announced interim CEO, Herv Brailly Yannis Morel broadens remit to Chief O
Innate Pharma has announced the appointment of two new members to its Executive Board, enhancing its leadership structure under interim CEO Herv Brailly. Arvind Sood, formerly of Amgen, takes on the role of Executive Vice President and President of US Operations, while Sonia Quaratino, the current Chief Medical Officer, joins the board as well. These changes aim to strengthen Innate's position in the US market and advance its innovative cancer immunotherapy pipeline. The leadership team is focused on leveraging their combined experience to drive the company's strategic initiatives.
Read more →IPHANumber of Shares and Voting Rights of Innate Pharma as of
As of January 1, 2024, Innate Pharma has announced its total number of shares outstanding and voting rights. The company has 80,860,563 ordinary shares and a total of 81,617,753 theoretical voting rights. Innate Pharma continues to advance its development in immunotherapies targeting various types of cancer, demonstrating its active role in the biopharmaceutical sector. This announcement is part of the regulatory requirements under French law regarding shareholder transparency.
Read more →IPHARecent Developments Since
Innate Pharma recently announced interim efficacy results from the TELLOMAK Phase 2 study for lacutamab in mycosis fungoides, showcasing a favorable safety profile. The company also reported a strong cash position of $121.9 million, although its revenue for the first nine months of 2023 decreased compared to last year. New leadership was introduced with the appointment of Dr. Sonia Quaratino as Chief Medical Officer, bringing extensive experience in clinical development. However, a partial clinical hold on lacutamab trials was initiated by the FDA following a serious adverse event. The company also provided updates on its ongoing and upcoming clinical trials amid these developments.
Read more →IPHA▲ +9.8%on this newsshared move
Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi Sanofi to exercise one option to license a new ANKET program from Innate; After a research collaboration period, Sanofi will
Innate Pharma has announced that Sanofi has exercised an option to license a new natural killer (NK) cell engager program from its ANKET platform for oncology. Following a successful research collaboration since 2016, Sanofi will take responsibility for the development, manufacturing, and commercialization of the program. Innate will receive a €15 million payment upon the exercise of this option and is eligible for up to €1.35 billion in future milestones and royalties. This milestone enhances their ongoing collaboration and the development of innovative cancer treatments.
Read more →IPHAInnate Pharma Announces Leadership Change Current CEO Mondher Mahjoubi to leave Innate Pharma to pursue an opportunity at a large pharmaceutical company Current Chairman of the Supervisory Board, former CEO and company c
Innate Pharma announced leadership changes as CEO Mondher Mahjoubi resigns to pursue a new opportunity at a large pharmaceutical company. Herv Brailly, current Chairman of the Supervisory Board and co-founder, has been appointed as the interim CEO, while Irina Staatz-Granzer takes over as Chairwoman of the Supervisory Board. The changes are expected to strengthen the Executive Board in 2024, although the departure of Mahjoubi could introduce transitional uncertainties within the company's operations and strategy.
Read more →IPHAInnate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With S zary Syndrome at ASH 2023 Results confirm promising clinical activity, durable responses and favorable safety of lacut
Innate Pharma announced positive final results from the Phase 2 TELLOMAK study at the ASH 2023 Annual Meeting, demonstrating lacutamab's efficacy in patients with S zary Syndrome. The study showed an overall response rate of 37.5% among heavily pretreated patients, including complete and partial responses. Lacutamab also exhibited a favorable safety profile, with promising durability noted in response duration. The trial's completion allows for further long-term follow-up to assess key endpoints.
Read more →IPHA▼ -5.4%on this newsshared move
Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023 SAR443579/IPH6101, ANKET platform lead asset, is a first-in-class NKp46/CD16-based NK cel
Innate Pharma reported positive Phase 1/2 results for SAR443579/IPH6101, a novel NK cell engager targeting CD123, at the ASH 2023 conference. The study demonstrated significant clinical benefits, including five complete remissions in patients with relapsed or refractory acute myeloid leukemia (AML). With a good safety profile, the drug remains a promising candidate for treating blood cancers with high unmet medical needs. Innate continues to collaborate with Sanofi aimed at advancing this unique therapy in oncology.
Read more →IPHAInnate Pharma to Host Virtual KOL Event on Lacutamab The event will highlight positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory S zary syndrome wh
Innate Pharma will host a virtual KOL event on December 12, 2023, focusing on lacutamab's positive results from the TELLOMAK Phase 2 Trial in patients with relapsed and refractory S zary syndrome. The presentation will highlight data showing promising clinical activity and a favorable safety profile for lacutamab in a heavily pre-treated patient population. Key opinion leaders, including Prof. Pierluigi Porcu, will discuss the findings, which will also be presented at the American Society of Hematology Annual Meeting.
Read more →IPHA▲ +13.7%on this news
Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update Positive final results of lacutamab TELLOMAK Phase 2 trial in S zary syndrome selected for oral presentation and preliminary data in Peripher
Innate Pharma announced its third quarter financial results and provided a business update, highlighting positive final results from the lacutamab TELLOMAK Phase 2 trial in S zary syndrome, which will be presented at the upcoming ASH Annual Meeting. The company reported a strong cash position of 121.9 million, with a projected cash runway extending into the second half of 2025. However, a partial clinical hold was placed by the FDA on the lacutamab IND following a case of hemophagocytic lymphohistiocytosis, impacting new patient enrolment in certain trials. Despite this, several promising developments in the pipeline, including the progression of proprietary assets, were also highlighted.
Read more →IPHAInnate Pharma Announces Conference Call for Third Quarter 2023 Business Update MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma has scheduled a conference call for November 14, 2023, to provide an update on its business progress in Q3 2023. The call will feature key executives including the CEO and the Chief Medical Officer. The company is focused on developing immunotherapies for cancer, leveraging its ANKET platform and collaborations with partners like AstraZeneca and Sanofi. However, it acknowledges the inherent risks and uncertainties involved in its ongoing clinical trials and regulatory processes.
Read more →IPHA▲ +18.4%on this newsshared move
Innate Pharma Announces New Clinical Data for Lacutamab and SAR443579/IPH6101 at ASH 2023 Positive results from the TELLOMAK Phase 2 Trial with lacutamab in heavily pretreated patients with relapsed and refractory S zary
Innate Pharma announced positive clinical data for their therapy, lacutamab, at the 65th ASH Annual Meeting. The TELLOMAK Phase 2 trial highlighted a 37.5% Objective Response Rate in patients with relapsed and refractory Sezary syndrome. Additional presentations will include promising findings for SAR443579/IPH6101 in treating blood cancers. These results suggest potential advancement in targeted therapies for patients with high unmet needs.
Read more →IPHAInnate Pharma Announces Its Participation to Upcoming Investor Conferences MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma announced its participation in several upcoming investor conferences scheduled for November 2023. These events include the Jefferies London Healthcare Conference and the Evercore ISI HealthCONx Conference in Miami and Paris. The company's innovative approach focuses on developing immunotherapies for cancer, leveraging partnerships with major firms like Sanofi and AstraZeneca. Innate Pharma aims to enhance its visibility and stakeholder engagement through these conferences.
Read more →IPHA▼ -8.8%on this news
Innate Pharma 2024 Financial Calendar MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma has announced its financial calendar for the year 2024, detailing key dates for financial statements and a shareholders meeting. The company, known for its advancements in cancer immunotherapy through its proprietary ANKET platform, continues to focus on innovation. Stakeholders can expect significant updates, particularly regarding the development of its lead programs such as lacutamab and collaborations with major partners. The communications will be made prior to market opening on the specified dates.
Read more →IPHAInnate Pharma Announces Abstracts Selected for ESMO Congress 2023 Sanofi's ongoing SAR'579/IPH6101 Phase 1/2 trial in hematologic malignancies selected for oral presentation Presentations under the AstraZeneca collaborat
Innate Pharma has announced the selection of several abstracts for presentation at the ESMO Congress 2023 in Madrid, including a key oral session focused on its ongoing phase 1/2 clinical trial of SAR'579/IPH6101 for hematologic malignancies. Additionally, the company will showcase presentations related to its collaborations with AstraZeneca, including early-stage lung cancer treatment and updates on monalizumab for squamous cell carcinoma. This showcase reflects the company's commitment to advancing innovative immunotherapies.
Read more →IPHAInnate Pharma Provides Update on Lacutamab Clinical Program Phase 2 TELLOMAK trial fully recruited, final data expected Q4 2023 Phase 1b PTCL trial awaiting futility interim analysis, preliminary data expected Q4 2023 US
Innate Pharma has announced updates regarding its lacutamab clinical program, indicating that the Phase 2 TELLOMAK trial has completed patient recruitment, with final data expected in Q4 2023. However, the FDA has placed a partial clinical hold on the lacutamab IND, pausing new patient enrollment following a reported severe adverse reaction. The company's Phase 1b PTCL trial is also awaiting interim analysis, with preliminary data anticipated in the same timeframe. Patient safety remains a top priority as the company works to address the FDA's requests.
Read more →IPHAInnate Pharma Announces Encore Presentation of Interim Results of Phase 2 TELLOMAK Study With Lacutamab With Updated Olsen 2022 Criteria at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023 Efficacy results,
Innate Pharma has presented interim results from the Phase 2 TELLOMAK study at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting 2023. The efficacy results indicate a global objective response rate (ORR) of 42.9% for lacutamab among patients with advanced Mycosis Fungoides, confirming its clinical activity. The study analyzed responses based on updated lymph node classification criteria, emphasizing the drug's favorable safety profile and potential as a treatment option in difficult cases. Further final results from the ongoing study are expected later this year.
Read more →IPHAInnate Pharma Reports First Half 2023 Financial Results and Business Update Phase 1/2 dose escalation safety and preliminary efficacy of ANKET NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tol
Innate Pharma has reported its financial results for the first half of 2023, highlighting strong progress in its clinical pipeline, particularly with the ANKET NK cell engager SAR'579/IPH6101, which received positive safety and efficacy indications in early trials. The company also announced a partnership with Takeda, granting exclusive rights to develop antibody drug conjugates, which includes a significant upfront payment and potential future milestones. With a solid cash position of $124.7 million, Innate forecasts continued operational momentum through 2025, alongside leadership changes and ongoing clinical trials for their pipeline products.
Read more →IPHAInnate Pharma Announces Its Participation to Upcoming Investor Conferences and Conference Call for First Half 2023 Business Update MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma has announced plans for its management team to participate in several upcoming investor conferences and will hold a conference call on September 14, 2023, to discuss business updates for the first half of 2023. The events include Citi's BioPharma Conference, H.C. Wainwright's Global Investment Conference, and Morgan Stanley's Global Healthcare Conference. The company aims to share its progress in developing immunotherapies, including its lead program lacutamab for specific types of lymphomas.
Read more →IPHAInnate Pharma to Participate in Upcoming Investor Conference MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma SA will participate in the H.C. Wainwright Immune Cell Engager Virtual Conference on August 17, 2023. The company, based in Marseille, France, specializes in developing immunotherapies for cancer, utilizing its proprietary ANKET platform. Its portfolio includes significant products like lacutamab and monalizumab, demonstrating its commitment to advancing cancer treatments. Collaborations with biopharmaceutical companies and research institutions further underscore Innate Pharma's strategic position in the industry.
Read more →IPHAFirst Patient Dosed in SAR'514 / IPH6401 Phase 1/2 Clinical Trial in Relapsed/Refractory Multiple Myeloma Partner Sanofi advances SAR'514 / IPH6401, a trifunctional anti-BCMA NKp46xCD16 NK cell engager from a joint resea
Innate Pharma has announced the dosing of the first patient in a Phase 1/2 clinical trial for SAR'514 / IPH6401, a candidate targeted at relapsed/refractory Multiple Myeloma and Light-chain Amyloidosis. This trial is part of a collaboration with Sanofi, with the aim of assessing the treatment's safety and preliminary efficacy. SAR'514 utilizes a novel trifunctional NK cell engager technology, which seeks to enhance NK cell activation against cancer cells. This milestone has triggered a milestone payment from Sanofi to Innate, underscoring the strategic partnership between the two companies.
Read more →IPHAFirst Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer Phase 2 MATISSE trial is evaluating IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with Imfinzi (durvalumab) and chem
Innate Pharma recently announced that the first patient has been dosed in the Phase 2 MATISSE trial for its drug IPH5201, an anti-CD39 monoclonal antibody. The trial evaluates the efficacy of IPH5201 in combination with AstraZeneca's Imfinzi and chemotherapy in treating early stage non-small cell lung cancer. The study aims to assess antitumor activity and safety in patients with resectable tumors. The collaboration with AstraZeneca underscores the support in trial execution and drug supply. Despite potential benefits, the trial's early status brings inherent uncertainties regarding patient outcomes.
Read more →IPHA▲ +6.7%on this news
Innate Pharma Highlights Increased Lacutamab Clinical Activity From Interim Results of Phase 2 TELLOMAK Study With Updated Olsen Criteria Efficacy results presented at the 17th International Conference on Malignant Lymph
Innate Pharma reported increased clinical activity for lacutamab based on interim results from the Phase 2 TELLOMAK study presented at the 17th International Conference on Malignant Lymphoma. The updated results showed a global objective response rate (ORR) of 42.9% in advanced Mycosis Fungoides patients. The findings also confirmed a favorable safety profile for lacutamab, which is a novel anti-KIR3DL2 antibody. Additional insights from experts highlighted the potential impact of updated lymph node evaluation guidelines on treatment outcomes.
Read more →IPHA▲ +8.4%on this news
Innate Pharma to Present Updated Interim Phase 2 Efficacy Results of Lacutamab in Mycosis Fungoides at the International Conference on Malignant Lymphoma Efficacy results of lacutamab in Mycosis Fungoides according to up
Innate Pharma is set to present updated interim efficacy results from its TELLOMAK Phase 2 study of lacutamab in advanced Mycosis Fungoides at the International Conference on Malignant Lymphoma. The presentation will focus on efficacy results based on updated lymph node classifications. Lacutamab is a humanized antibody that has shown promise in treating cutaneous T-cell lymphoma and received fast-track designations from both the EMA and FDA. The study offers potential progress in a therapeutic area with few effective options for patients.
Read more →IPHA▲ +8.4%on this newsshared move
Innate Pharma Highlights Proprietary Tetra-specific ANKET NK Cell Engager IPH6501 at the EHA 2023 Congress IPH6501 is a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic, based on ANKET
Innate Pharma has presented promising data on its novel tetra-specific NK cell engager, IPH6501, at the EHA 2023 Congress. This investigational therapy, targeting CD20, is designed for the treatment of B-cell non-Hodgkin's lymphomas and is set to enter Phase 1 trials in 2023. The preclinical results indicate substantial NK cell activation and efficacy against malignancies, indicating a potentially innovative therapeutic option for patients in need. Innate is positioned as a leader in the development of next-generation immunotherapies utilizing its proprietary ANKET platform.
Read more →IPHA▲ +10.3%on this newsshared move
SAR'579 / IPH6101 Receives FDA Fast Track Designation in the US for the Treatment of Hematological Malignancies SAR'579, ANKET platform lead asset, is a trifunctional anti-CD123 NKp46 CD16 NK cell engager from a joint re
Innate Pharma announced that SAR'579/IPH6101 has received Fast Track Designation from the FDA for the treatment of hematological malignancies. This designation aims to accelerate the development and review processes for important medications addressing serious health needs. The therapy is part of the ANKET platform, aimed at enhancing cancer treatment through NK cell engagement. Innate Pharma collaborates with Sanofi for the development and commercialization of this promising drug.
Read more →IPHAInnate Pharma Highlights Phase 1/2 Dose Escalation Safety and Preliminary Efficacy of Sanofi Developed First NK Cell Engager SAR'579 / IPH6101 in R/R AML SAR'579/IPH6101, ANKET platform lead asset, is a trifunctional ant
Innate Pharma announced positive preliminary data from a Phase 1/2 dose escalation study of its NK cell engager SAR'579/IPH6101 in patients with relapsed or refractory acute myeloid leukemia (R/R AML). The results demonstrated that SAR'579 was well tolerated and led to three complete responses among eight patients at the highest tested dose. These findings will be further discussed in an upcoming oral presentation at the ASCO 2023 Annual Meeting, marking a significant step forward for Innate's ANKET platform in cancer treatment.
Read more →IPHAInnate Pharma to Participate in Upcoming Investor Conferences MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma SA has announced that its senior management team will participate in various upcoming investor conferences, including the ASCO 2023 Annual Meeting and the Jefferies Healthcare Conference. The firm, focused on developing immunotherapies through its proprietary ANKET platform, aims to address multiple cancer types. These conferences provide an opportunity for the company to showcase its innovative cancer treatments and strengthen partnerships within the biopharmaceutical industry.
Read more →IPHAInnate Pharma to Present IPH6501 Preclinical Data at The EHA 2023 Congress IPH6501, a first-in-class tetra-specific antibody-based natural killer cell engager therapeutic developed for the treatment of B-cell non-Hodgkin
Innate Pharma has announced that its preclinical data on the IPH6501 therapeutic will be presented at the EHA 2023 congress from June 8 to 15 in Frankfurt. This innovative therapy, a tetra-specific antibody-based natural killer cell engager, is designed for treating B-cell non-Hodgkin's lymphomas. With its unique approach to activating NK cells and engaging tumor antigens, IPH6501 represents a significant advancement in the field of cancer immunotherapy. The company is moving forward with plans for a Phase 1 clinical trial within the year.
Read more →IPHAOutcome of Innate Pharma's 2023 Annual General Meeting MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma SA held its 2023 Annual General Meeting in Marseille on May 12, where all shareholder resolutions were successfully voted on. A quorum of 44.928% was reached, with 112 votes cast representing the voting rights of over 36 million shares. All seven members of the Supervisory Board who were up for election were re-elected, signifying support for the current leadership. The company continues to develop advanced immunotherapies for cancer patients, leveraging its proprietary platforms.
Read more →IPHAInnate Pharma Reports First Quarter 2023 Financial Results and Business Update Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodi
Innate Pharma has reported its financial results for Q1 2023, highlighting a new exclusive partnership with Takeda for the development of antibody drug conjugates. This collaboration grants Takeda worldwide rights and includes an upfront payment of $5 million, with potential future milestones totaling up to $410 million. The company's strong cash position is expected to support operations into mid-2025, while ongoing clinical developments include significant presentations planned at the upcoming ASCO 2023 meeting. Innate is focused on leveraging its scientific expertise and partnerships to enhance treatment options for cancer patients.
Read more →IPHAInnate Pharma Announces Conference Call and Webcast for Q1 Business Update MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma has announced a conference call and webcast scheduled for May 10, 2023, to provide an update on its business progress for the first quarter of 2023. The update will feature key executives, including the CEO and CMO, highlighting leadership involvement. Innate Pharma focuses on developing immunotherapies for cancer patients, utilizing its proprietary ANKET platform and collaborations with industry partners like AstraZeneca and Sanofi.
Read more →IPHAInnate Pharma Highlights Clinical Abstracts Selected for ASCO 2023 Annual Meeting Oral presentation on SAR'579 / IPH6101, a potential first-in-class NKp46/CD16-based NK cell engager targeting CD123; SAR'579 / IPH6101 is
Innate Pharma announced that three clinical abstracts, including their lead asset SAR'579, have been selected for presentation at the ASCO 2023 Annual Meeting. SAR'579 is a first-in-class NK cell engager targeting CD123 and is developed in partnership with Sanofi. Two other abstracts relate to monalizumab in non-small cell lung cancer studies conducted with AstraZeneca. The presentations are scheduled during the meeting set for June 2-6, 2023, in Chicago, reflecting Innate's ongoing commitment to advancing cancer immunotherapy.
Read more →IPHAInnate Pharma Establishes a New At-The-Market ("ATM") Program on Nasdaq MARSEILLE, France- (BUSINESS WIRE)
Innate Pharma has launched a new At-The-Market (ATM) program on Nasdaq, allowing the sale of up to $75 million in American Depositary Shares (ADS) to eligible investors. This program is intended to fund research and development expenses and general corporate purposes. The company has terminated its previous ATM program as of April 19, 2023. Shareholders may experience potential dilution, with a maximum estimated impact of 22.97% based on the new share issuance.
Read more →IPHAInnate Pharma to Hold Its Annual General Meeting of Shareholders on
Innate Pharma will host its Annual General Meeting of Shareholders (AGM) on May 12, 2023, at its headquarters in Marseille, France. The AGM will be livestreamed, ensuring shareholder participation and transparency. Important details regarding required registration and documentation were provided, emphasizing the need for shareholders to prepare on time. Innate Pharma continues to focus on developing innovative cancer immunotherapies through partnerships and their proprietary technology platforms.
Read more →IPHAInnate Pharma Files Its 2022 Universal Registration Document ( D ocument d'enregistrement universel ) and 2022 Annual Report on Form 20-F MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma announced the filing of its 2022 Universal Registration Document and Annual Report on Form 20-F with relevant authorities. The documents detail the company's ongoing efforts in developing immunotherapies for various cancers, highlighting its proprietary therapeutic platforms. Innate Pharma's partnerships with major biopharmaceutical entities underscore its collaborative approach in advancing cancer treatment. However, the filings also mention the uncertainties and risks associated with research, regulatory approval processes, and the need for ongoing capital funding.
Read more →IPHA▲ +10.5%on this newsshared move
Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program Takeda to obtain exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) u
Innate Pharma has announced an exclusive license agreement with Takeda for the development of antibody drug conjugates targeting celiac disease. Takeda will manage the future development, manufacturing, and commercialization of any products developed from this collaboration. Innate will receive an upfront payment of $5 million, with potential earnings from future milestones totaling up to $410 million. This partnership expands Innate Pharma's research applications beyond oncology, leveraging their antibody engineering expertise.
Read more →IPHA▼ -11.9%on this news
Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update Sanofi collaboration for Natural Killer cell engager therapeutics expanded to B7-H3 ANKET program and two additional targets, with 25 million
Innate Pharma (IPHA) has announced its financial results for the year ending December 31, 2022, highlighting significant advancements in its clinical pipeline. The company expanded its collaboration with Sanofi for NK Cell Engager Therapeutics, receiving a $25 million payment. Early efficacy signals for lacutamab in advanced cutaneous T cell lymphoma were released, with final results expected in late 2023. Additionally, Innate's cash position stands at $136.6 million, providing strategic support for upcoming trials and initiatives.
Read more →IPHA▼ -5.5%on this news
Innate Pharma Announces Conference Call and Webcast for Full Year 2022 Financial Results MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma has announced a conference call scheduled for March 23, 2023, to discuss its financial results for the year ending December 31, 2022. The call will feature key company executives, including the CEO and CFO, highlighting the company's commitment to transparency and investor relations. Innate Pharma is recognized for its innovative cancer therapies and has a robust pipeline involving various industry collaborations. However, the company also warns of inherent risks and uncertainties associated with its development projects and financial status.
Read more →IPHAInnate Pharma Provides Update on Silicon Valley Bank Exposure Innate Pharma does not have any financial exposure to Silicon Valley Bank MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma has confirmed that it has no financial exposure to Silicon Valley Bank, which has been closed by regulatory authorities. The company clarifies that its cash and investment portfolio are unaffected by the bank's receivership. Additionally, Innate Pharma's liquidity and operations remain stable, allowing it to focus on its oncology pipeline. This statement follows recent market concerns regarding the bank's failure.
Read more →IPHAInnate Pharma Announces HSR Clearance Regarding Expansion of Its Collaboration With Sanofi on NK Cell Engagers Following expiration of Hart-Scott-Rodino waiting period regarding expansion of their collaboration on NK cel
Innate Pharma has announced the expiration of the Hart-Scott-Rodino waiting period, making its collaboration expansion with Sanofi official. This partnership includes a licensing agreement for a Natural Killer (NK) cell engager program targeting B7H3 from Innate's ANKET platform. The agreement secures an upfront payment of $25 million and potential milestone payments totaling up to $1.35 billion, as well as royalties on net sales. This collaboration may enhance treatment options for cancer patients through advanced NK cell technologies.
Read more →IPHA▲ +8.1%on this news
Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology Data show control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK
Innate Pharma has published preclinical data in Nature Biotechnology demonstrating the effectiveness of a trifunctional NK cell engager (NKCE) targeting CD123 to control acute myeloid leukemia (AML). The studies indicate that this novel NKCE surpasses current anti-CD123 therapies in terms of antitumor activity and safety. This discovery supports the ongoing Phase 1/2 clinical trial sponsored by Sanofi, which is assessing the NKCE's performance in patients with relapsed or refractory AML. Experts from Innate and Sanofi express optimism about the potential of this innovative cancer treatment.
Read more →IPHA▲ +39.5%on this news
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology Sanofi gains exclusive license to Innate's B7H3 ANKET TM program and options for two additional targets; Upon candidate selec
Sanofi and Innate Pharma Expand Collaboration for Natural Killer Cell Therapeutics in Oncology Sanofi gains exclusive license to Innate's B7H3 ANKETTM program and options for two additional targets; Upon candidate selection, Sanofi will be responsible for all development, manufa
Read more →IPHANUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 1, 2022 Marseille, France
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF DECEMBER 1, 2022 Marseille, France, December 12, 2022, 6:00 AM CET Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorit des March s
Read more →IPHAInnate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced S zary Syndrome at ASH 2022 Lacutamab demonstrated encouraging efficacy and a favorable safety prof
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced S zary Syndrome at ASH 2022 Lacutamab demonstrated encouraging efficacy and a favorable safety profile in heavily pretreated, post-mogamulizumab patients with
Read more →IPHA▲ +6.5%on this news
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022 Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, as monotherapy or in combination with durvalumab, in advanced solid tumors
Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022 Phase 1 data for IPH5201, a CD39-blocking monoclonal antibody, as monotherapy or in combination with durvalumab, in advanced solid tumors to be presented by partner AstraZeneca Preclinical data su
Read more →IPHA▲ +8.3%on this news
Innate Pharma Reports Third Quarter Financial Results Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Prelimin
Innate Pharma Reports Third Quarter Financial Results Preliminary data from ongoing Phase 2 TELLOMAK trial of lacutamab demonstrated clinical activity in mycosis fungoides, presented at EORTC-CLTG annual meeting Preliminary Sezary syndrome lacutamab Phase 2 data to be presented
Read more →IPHAInnate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2022 Business Update MARSEILLE, France--(BUSINESS WIRE)--November 7, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company w
Read more →IPHAInnate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET Platform at ASH 2022 Innate will share preliminary results of the cohort eval
Innate Pharma to Present Results From a Preliminary Analysis of the TELLOMAK Phase 2 Trial in Patients With Advanced Sezary Syndrome and ANKET Platform at ASH 2022 Innate will share preliminary results of the cohort evaluating lacutamab in Sezary syndrome patients post-mogamuliz
Read more →IPHAInnate Pharma 2023 Financial Calendar MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma 2023 Financial Calendar MARSEILLE, France--(BUSINESS WIRE)--October 20, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2023 financial calendar: March 23, 2023: Publication of 2022 financ
Read more →IPHA▼ -5.7%on this news· ran to -17% by day 3
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides Preliminary data set presented at EORTC CLTG annual meeting confirms clinical act
Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Mycosis Fungoides Preliminary data set presented at EORTC CLTG annual meeting confirms clinical activity and favorable safety profile of lacutamab in patients
Read more →IPHAInnate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Announces Conference Call and Webcast for First Half 2022 Business Update MARSEILLE, France--(BUSINESS WIRE)--September 8, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company wil
Read more →IPHA▼ -9.1%on this newsshared move
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET Platform at ESMO 2022 Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on mul
Innate Pharma to Present Lacutamab PTCL Phase 1b Design and ANKET Platform at ESMO 2022 Poster presentation on ongoing lacutamab Phase 1b trial design in monotherapy in peripheral T-cell lymphoma Oral presentation on multispecific antibodies: ANKET for antigen-specific activati
Read more →IPHA▼ -12.2%on this news
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study MARSEILLE, France--(BUSINESS WIRE)--August 1, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that a planned futility interi
Read more →IPHASecond Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development IPH6401/SAR'514 is a BCMA-targeting NK cell engager using Sanofi's proprietary CROSSODILE multi-functional platform. It was develo
Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development IPH6401/SAR'514 is a BCMA-targeting NK cell engager using Sanofi's proprietary CROSSODILE multi-functional platform. It was developed jointly and benefits from the dual NK targeting of Inna
Read more →IPHAInnate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer Anti-CD39 monoclonal antibody IPH5201 advances to Phase 2 study in lung cancer Innate to receive $5M milestone payment from AstraZeneca MARSEILLE, France--(BUS
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer Anti-CD39 monoclonal antibody IPH5201 advances to Phase 2 study in lung cancer Innate to receive $5M milestone payment from AstraZeneca MARSEILLE, France--(BUSINESS WIRE)--June 3, 2022--Regulatory News: Innate Pharm
Read more →IPHAOutcome of Innate Pharma's 2022 Annual General Meeting Appointment of Dr Sally Bennett to the Supervisory Board MARSEILLE, France--(BUSINESS WIRE)
Outcome of Innate Pharma's 2022 Annual General Meeting Appointment of Dr Sally Bennett to the Supervisory Board MARSEILLE, France--(BUSINESS WIRE)--May 20, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") announced the vot
Read more →IPHAInnate Pharma Reports First Quarter 2022 Financial Results and Business Update First patient dosed in monalizumab Phase 3 lung cancer trial, PACIFIC-9 sponsored by AstraZeneca, which triggered a $50 million milestone pay
Innate Pharma Reports First Quarter 2022 Financial Results and Business Update First patient dosed in monalizumab Phase 3 lung cancer trial, PACIFIC-9 sponsored by AstraZeneca, which triggered a $50 million milestone payment extending Company cash runway into 2024 Monalizumab d
Read more →IPHAInnate Pharma Establishes an At-The-Market ("ATM") Program on Nasdaq MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Establishes an At-The-Market ("ATM") Program on Nasdaq MARSEILLE, France--(BUSINESS WIRE)--May 3, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that it has filed a prospectus supplement with
Read more →IPHA6xk 2020 Innate Pharma. All rights reserved. PARIS: IPH.PA NASDAQ: IPHA Company Overview April 2022 This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to inves
This document has been prepared by Innate Pharma S.A. (the "Company") solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The
Read more →IPHAInnate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Announces Conference Call and Webcast for Q1 2022 Business Update MARSEILLE, France--(BUSINESS WIRE)--May 3, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a confe
Read more →IPHA▲ +6.3%on this newsshared move
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca First patient dosed in Phase 3 trial, PACIFIC-9, evaluating durvalumab in combination with monal
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca First patient dosed in Phase 3 trial, PACIFIC-9, evaluating durvalumab in combination with monalizumab or oleclumab in patients with unresectable, Stage II
Read more →IPHAInnate Pharma Files Its 2021 Universal Registration Document ( Document d'enregistrement universel ) and 2021 Annual Report on Form 20-F MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Files Its 2021 Universal Registration Document ( Document d'enregistrement universel ) and 2021 Annual Report on Form 20-F MARSEILLE, France--(BUSINESS WIRE)--April 5, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Co
Read more →IPHAInnate Pharma Reports Full Year 2021 Financial Results and Business Update Monalizumab progressing to Phase 3 PACIFIC-9 lung cancer clinical trial in partnership with AstraZeneca First CD123 tri-specific ANKET TM starts
Innate Pharma Reports Full Year 2021 Financial Results and Business Update Monalizumab progressing to Phase 3 PACIFIC-9 lung cancer clinical trial in partnership with AstraZeneca First CD123 tri-specific ANKETTM starts Phase 1 study by Sanofi Lacutamab encouraging MF data and
Read more →IPHAInnate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Announces Conference Call and Webcast for Full Year 2021 Financial Results MARSEILLE, France--(BUSINESS WIRE)--March 17, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will
Read more →IPHAInnate Pharma Obtains 28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans Financing strengthens Company's cash horizon MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Obtains 28.7m in Non-Dilutive Financing in the Form of State Guaranteed Loans Financing strengthens Company's cash horizon MARSEILLE, France--(BUSINESS WIRE)--January 5, 2022--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the
Read more →IPHAInnate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers Partner Sanofi advances IPH6101/ SAR443579, a novel NKp46/CD16-based, CD123 targeted NK cell engager, to first-in-
Innate Pharma: First Patient Dosed in IPH6101/SAR443579 Phase 1/2 Clinical Trial in Various Blood Cancers Partner Sanofi advances IPH6101/ SAR443579, a novel NKp46/CD16-based, CD123 targeted NK cell engager, to first-in-human clinical trial in relapsed/refractory AML, B-ALL or H
Read more →IPHAInnate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress First chemo-free triplet
Innate Pharma: Monalizumab Combined With Cetuximab and Durvalumab Demonstrates Anti-Tumor Activity in First-Line Recurrent or Metastatic Head and Neck Cancer at ESMO Immuno-Oncology 2021 Congress First chemo-free triplet shows preliminary activity and an acceptable safety profil
Read more →IPHA▼ -6.1%on this news
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress Innate to present new Phase 2 data on the combination of monalizumab, cetuximab and durvalumab in head and neck cancer in an oral presentati
Innate Pharma to Present Monalizumab Data at ESMO Immuno-Oncology 2021 Congress Innate to present new Phase 2 data on the combination of monalizumab, cetuximab and durvalumab in head and neck cancer in an oral presentation ANKETTM to be highlighted in ESMO IO educational sessio
Read more →IPHAInnate Pharma to Participate in the Evercore ISI 4 th Annual HealthConX Virtual Conference MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma to Participate in the Evercore ISI 4 th Annual HealthConX Virtual Conference MARSEILLE, France--(BUSINESS WIRE)--November 24, 2021--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that members of it
Read more →IPHAInnate Pharma Third Quarter 2021 Report Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca's randomized Phase 2 COAST study in unresectable, Stage III NSCLC, advancing to
Innate Pharma Third Quarter 2021 Report Monalizumab in combination with durvalumab significantly delayed disease progression in AstraZeneca's randomized Phase 2 COAST study in unresectable, Stage III NSCLC, advancing to Phase 3 Pre-clinical data presented at SITC with Sanofi fr
Read more →IPHAInnate Pharma Highlights New NK Cell Engager Data With Partner Sanofi at SITC Annual Meeting The companies will present pre-clinical data on Innate's lead ANKET TM asset, IPH6101/ SAR443579, the first NKp46/CD16-based NK
Innate Pharma Highlights New NK Cell Engager Data With Partner Sanofi at SITC Annual Meeting The companies will present pre-clinical data on Innate's lead ANKETTM asset, IPH6101/ SAR443579, the first NKp46/CD16-based NK cell engager targeting CD123 These data highlight molecule
Read more →IPHAInnate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma Announces Conference Call and Webcast for Q3 2021 Business Update MARSEILLE, France--(BUSINESS WIRE)--November 9, 2021--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), today announced that the Company will hold a
Read more →IPHA▲ +7.2%on this news
Innate Pharma 2022 Financial Calendar MARSEILLE, France--(BUSINESS WIRE)
Innate Pharma 2022 Financial Calendar MARSEILLE, France--(BUSINESS WIRE)--October 26, 2021--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today released its 2022 financial calendar: March 24, 2022: Publication of 2021 financ
Read more →Competitive Position
How IPHA ranks across every disease it competes inCompetitive Position is a premium feature
See how IPHA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial